- FEDERAL FINDINGS & CLINICAL EVIDENCE
Cannabis has proven medical use and low abuse potential.
That's not an advocacy position — it's the official determination of the U.S. Department of Health and Human Services and the White House. Federal agencies have formally found that cannabis treats recognized medical conditions and carries less abuse potential than substances currently in Schedule I or II. This page presents those findings alongside the clinical evidence that supports them.
"Cannabis has a currently accepted medical use in treatment in the United States and has a potential for abuse less than the drugs or other substances in Schedules I and II."
— U.S. Department of Health and Human Services, 2023 Scheduling Recommendation to the Drug Enforcement Administration
OFFICIAL FEDERAL DETERMINATIONS
What the U.S. government has concluded
The federal government's own expert agencies have made formal, official determinations that cannabis has accepted medical use and a lower potential for abuse than substances currently in Schedule I or II. These are not advocacy positions. They are the conclusions of scientific reviews conducted under the Controlled Substances Act's own procedures.
White House, 2025: medical value of cannabis recognized
President Trump's December 2025 executive order on cannabis documented that more than 30,000 licensed healthcare practitioners across 40 states are authorized to recommend medical cannabis to more than 6 million registered patients for at least 15 medical conditions. The order acknowledged that the HHS recommendation was based in part on FDA's finding of credible scientific support for cannabis in treating pain, anorexia, and chemotherapy-induced nausea. On April 23, 2026, in response to President Trump's order, Acting Attorney General Todd Blanche placed state-regulated medical cannabis products into Schedule III of the Controlled Substances Act — the most consequential shift in federal cannabis reform in more than five decades. White House EO, December 18, 2025.
HHS, 2023: a thorough analysis
In August 2023, the U.S. Department of Health and Human Services (HHS) completed a full scientific and medical evaluation of cannabis under the CSA's eight-factor test and transmitted a formal recommendation to the Drug Enforcement Administration (DEA) to move cannabis from Schedule I to Schedule III. The recommendation explicitly concluded that cannabis "has a currently accepted medical use in treatment in the United States" and "has a potential for abuse less than the drugs or other substances in Schedules I and II." This was the first time HHS had ever made such a recommendation for cannabis. HHS announcement, August 2023.
FDA: credible scientific support for specific conditions
As part of the HHS review, the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research evaluated clinical evidence and found credible scientific support for cannabis in the treatment of chronic pain, anorexia related to certain medical conditions (including HIV/AIDS wasting), and chemotherapy-induced nausea and vomiting. This was not a novel finding — FDA approved Marinol (dronabinol, Schedule III) for chemotherapy nausea in 1985 and for HIV wasting in 1992, and approved Epidiolex (cannabidiol) for severe pediatric epilepsy in 2018. These approvals establish that cannabinoids have recognized therapeutic value within FDA's own drug framework.
NIDA: concurrence on rescheduling
The National Institute on Drug Abuse (NIDA) — the federal agency specifically responsible for assessing drug abuse potential — formally concurred with FDA's recommendation that cannabis be rescheduled from Schedule I to Schedule III. In April 2024, the DEA proposed that rescheduling in the Federal Register. NIDA's concurrence directly contradicts the Schedule I classification's claim that cannabis has "a high potential for abuse" with "no accepted safety."
National Academies of Sciences, Engineering & Medicine, 2017
The National Academies' comprehensive 2017 review — the most rigorous independent evaluation of the evidence base — concluded that there is substantial or conclusive evidence that cannabis is effective for chronic pain in adults, muscle spasticity associated with multiple sclerosis, and chemotherapy-induced nausea and vomiting. The report reviewed more than 10,000 scientific abstracts and rated the evidence for these conditions at the highest level of certainty used in clinical evidence reviews. National Academies report.
OPIOID CRISIS & SUBSTITUTION
Medical cannabis reduces opioid prescriptions and overdose risk
One of the most consistent findings in the cannabis medical literature is that access to medical cannabis leads to meaningful reductions in opioid prescribing and use. In the context of the U.S. opioid epidemic — which kills approximately 80,000 Americans per year — this effect has major public health implications.
3.74M
16%
25%
How the substitution effect works
The evidence comes from multiple independent lines of research. The landmark 2016 Bradford & Bradford study examined Medicare Part D prescription data across all medical cannabis states from 2010 to 2015 and found that when medical dispensaries opened, there were 3.74 million fewer daily opioid doses prescribed per year. A broader 2024 analysis published in PLOS ONE found an average 16% reduction in opioid prescriptions in states with medical cannabis programs, controlling for demographics and other confounders. The effect was most pronounced for neuropathic pain, cancer pain, and chronic musculoskeletal pain.
These findings align with patient-reported data: multiple surveys of medical cannabis patients show that 40–60% report substituting cannabis for opioids, with most preferring cannabis due to lower perceived risks and better quality of life.
Veterans and PTSD
Veterans with PTSD are among the most common users of medical cannabis for symptom management, yet VA physicians are currently prohibited from recommending it despite 40 states authorizing it. A 2023 DAV report cited this as a documented policy gap. Veterans are disproportionately affected by both chronic pain and opioid use disorder — two conditions where the substitution evidence is most consistent.
THE GATEWAY THEORY
Federal agencies have debunked the gateway drug claim
The theory that cannabis use inevitably leads to harder drugs has been used to justify Schedule I classification for decades. Federal agencies — including the DEA, HHS, and CDC — have each reviewed this claim and found it unsupported by the evidence.
